Stock ALT ALTIMMUNE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Altimmune, Inc.

Equities

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 15/05/2024 BST 		5-day change 1st Jan Change
8.87 USD +13.43% Intraday chart for Altimmune, Inc. +23.88% -21.16%
05-09 Transcript : Altimmune, Inc., Q1 2024 Earnings Call, May 09, 2024
05-09 Earnings Flash (ALT) ALTIMMUNE Reports Q1 Revenue $5,000 MT

Business Summary

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Number of employees: 59

Sales per Business

USD in Million2022Weight2023Weight Delta
Treatments for Various Diseases and Disorders, and Vaccines
100.0 %
0 100.0 % 0 100.0 % -726.47%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 100.0 % 0 100.0 % -726.47%

Managers

Managers TitleAgeSince
Vipin K. Garg CEO
 Chief Executive Officer 67 29/11/18
Richard Eisenstadt DFI
 Director of Finance/CFO 66 30/12/21
Anthony Blandin CMP
 Compliance Officer - 31/01/22
M. Roberts CTO
 Chief Tech/Sci/R&D Officer 65 30/11/12
Bertrand Georges CTO
 Chief Tech/Sci/R&D Officer - 28/02/15
M. Harris CTO
 Chief Tech/Sci/R&D Officer 71 08/09/19
Karen Smith PRN
 Corporate Officer/Principal - 31/08/20
Andrew Shutterly AUD
 Comptroller/Controller/Auditor - 30/09/20
Karen Smith
56 -
Raymond Jordt PRN
 Corporate Officer/Principal 52 31/12/22

Members of the board

Members of the board TitleAgeSince
Mitchel Sayare CHM
 Chairman 76 31/03/10
Mack Gill BRD
 Director/Board Member 72 31/07/04
Philip Hodges BRD
 Director/Board Member 56 31/08/03
Vipin K. Garg CEO
 Chief Executive Officer 67 29/11/18
David Drutz BRD
 Director/Board Member 86 31/12/09
Wayne Pisano BRD
 Director/Board Member 69 29/08/18
Diane Jorkasky BRD
 Director/Board Member 72 10/05/20
Catherine Sohn BRD
 Director/Board Member 71 22/03/23
Klaus Schafer BRD
 Director/Board Member 74 30/06/12

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 70,902,191 70,351,925 ( 99.22 %) 0 99.22 %

Shareholders

NameEquities%Valuation
STATE STREET CORPORATION
12.20 %
8,649,270 12.20 % 62 M $
SSgA Funds Management, Inc.
12.20 %
8,649,270 12.20 % 62 M $
Threadneedle Asset Management Ltd.
5.661 %
4,013,211 5.661 % 29 M $
BlackRock Advisors LLC
5.451 %
3,864,446 5.451 % 28 M $
Vanguard Fiduciary Trust Co.
4.413 %
3,128,728 4.413 % 23 M $
Millennium Management LLC
4.107 %
2,911,937 4.107 % 21 M $
Tang Capital Management LLC
3.879 %
2,750,000 3.879 % 20 M $
Morgan Stanley Investment Management, Inc.
3.120 %
2,211,948 3.120 % 16 M $
Ameriprise Trust Co.
2.411 %
1,709,304 2.411 % 12 M $
Millennium Management LLC
2.243 %
1,590,150 2.243 % 11 M $

Company contact information

Altimmune, Inc.

910 Clopper Road Suite 201S

20878, Gaithersburg

+240 654 1450

http://www.altimmune.com
address Altimmune, Inc.(ALT)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Altimmune, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
8.87 USD
Average target price
20.71 USD
Spread / Average Target
+133.53%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ALTIMMUNE, INC. Stock Altimmune, Inc.
-21.16% 629M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+7.52% 113B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.38% 106B
ARGENX SE Stock argenx SE
+0.82% 22.27B
BIONTECH SE Stock BioNTech SE
-12.64% 22.22B
GENMAB A/S Stock Genmab A/S
-4.55% 19.43B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.85% 17.87B
BEIGENE, LTD. Stock BeiGene, Ltd.
-8.58% 17.24B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.77% 14.29B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.41% 12.52B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ALT Stock
  4. Company Altimmune, Inc.